The Library
Dapagliflozin : the outcome of use as add-on therapy in real-life clinical setting - an audit
Tools
Raja, Umar Yousaf and Saravanan, Ponnusamy (2021) Dapagliflozin : the outcome of use as add-on therapy in real-life clinical setting - an audit. JPMA. The Journal of the Pakistan Medical Association, 71 (9). pp. 2214-2216. doi:10.47391/JPMA.01-117 ISSN 0030-9982.
|
PDF
WRAP-Dapagliflozin-the-outcome-of-use-as-add-on-therapy-in-real-life-clinical-setting-an-audit-Saravanan-2021.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (283Kb) | Preview |
Official URL: https://doi.org/10.47391/JPMA.01-117
Abstract
Objectives: Dapagliflozin is the first novel sodium glucose co transporter 2 inhibitor for the treatment of Type 2 diabetes. The aim of this audit was to evaluate its effectiveness and safety in a real-life clinical setting.
Methods: We analyze data from four UK district general hospitals on patients initiated on dapagliflozin. HbA1c, weight and daily insulin dosage was recorded at baseline and 6 months follow-up.
Results: At baseline, mean HbA1c was 82±19.21mmol/mol(9.7%) and mean weight was 102±18.1kg. The average reduction in HbA1c at 6 months was 13±7.23 mmol/mol (1%) whereas the average reduction in weight was 2 ±2.02 kg.. A mean reduction in daily insulin requirement by 12±8.3 units at 6 months compared to baseline was noted. There were certain complications in patients taking insulin and gliclazide including candidiasis, urinary tract infection and hypoglycaemia, and 4% patients discontinued dapagliflozin due to side effects.
Conclusion: Our results confirm that dapagliflozin can be used safely and effectively in a real-life setting.
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Subjects: | Q Science > QP Physiology R Medicine > RC Internal medicine |
||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||
SWORD Depositor: | Library Publications Router | ||||
Library of Congress Subject Headings (LCSH): | Diabetes, Dapagliflozin, Outcome assessment (Medical care), Diabetes -- Treatment | ||||
Journal or Publication Title: | JPMA. The Journal of the Pakistan Medical Association | ||||
Publisher: | Pakistan Medical Association | ||||
ISSN: | 0030-9982 | ||||
Official Date: | September 2021 | ||||
Dates: |
|
||||
Volume: | 71 | ||||
Number: | 9 | ||||
Page Range: | pp. 2214-2216 | ||||
DOI: | 10.47391/JPMA.01-117 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Open Access (Creative Commons) | ||||
Date of first compliant deposit: | 21 February 2023 | ||||
Date of first compliant Open Access: | 23 February 2023 | ||||
Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year